INVESTOR DEADLINE: Boston Scientific Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – RGRD Law

Core Viewpoint - The Boston Scientific Corporation is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, with claims that the company misled investors regarding its financial outlook and market position [1][4]. Company Overview - Boston Scientific develops, manufactures, and markets medical devices for various interventional medical specialties globally [3]. Allegations of the Lawsuit - The lawsuit alleges that Boston Scientific and its executives made false or misleading statements about the company's revenue outlook and growth potential, downplaying risks from seasonality and macroeconomic factors [4]. - It is claimed that Boston Scientific's goal to grow its share in the electrophysiology market at "2x the market" was unrealistic due to new competition affecting its market share [4]. Financial Performance - On February 4, 2026, Boston Scientific reported its fourth quarter and full year 2025 financial results, revealing: - Fourth quarter GAAP net income of $672 million ($0.45 per share), up from $566 million ($0.38 per share) a year prior, with adjusted EPS of $0.80 compared to $0.70 a year ago [5]. - Full year GAAP net income of $2.898 billion ($1.94 per share), compared to $1.853 billion ($1.25 per share) the previous year, with full year adjusted EPS of $3.06 versus $2.51 a year ago [5]. - The reported GAAP net income per share of $0.45 fell short of the company's guidance range of $0.48 to $0.52, leading to a stock price drop of over 17% [5]. Lead Plaintiff Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Boston Scientific common stock during the class period to seek appointment as lead plaintiff in the lawsuit [6]. - The lead plaintiff represents the interests of all class members and can select a law firm for litigation [6]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025 alone [7]. - The firm has a strong track record, recovering $8.4 billion for investors over the past five years, including the largest securities class action recovery in history [7].